5-bromo-N-(4-chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide | 1223081-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-bromo-N-(4-chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide
• 英文别名: 5-bromo-N-[(4-chlorophenyl)methyl]-8-hydroxy-1,6-naphthyridine-7-carboxamide
• CAS: 1223081-62-6
• 化学式: C₁₆H₁₁BrClN₃O₂
• 分子量: 392.639
• InChiKey: NTAPBBIQPVCQQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-bromo-N-(4-chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 8-(((1r,4r)-4-aminocyclohexyl)amino)-5-bromo-N-(4-chlorobenzyl)-1,6-naphthyridine-7-carboxamide
  参考文献：
  名称：

  Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors

  摘要：

  1,6-萘啶结构是药物化学中的一种多价支架，在适当取代时表现出多种生物活性。通过在1,6-萘啶框架中引入一个环脲药效基，并通过对7、8位进行构象约束，所得到的1H-咪唑[4,5-h][1,6]萘啶-2(3H)-酮被确认为一种新的c-Met激酶抑制剂。全面的SAR研究表明，带有末端游离氨基的N-1烷基取代基、N-3位的疏水性取代苯基团以及三环核心对于保持1H-咪唑[4,5-h][1,6]萘啶-2(3H)-酮化合物的有效Met抑制至关重要。进一步在C-5位引入4′-氨甲酰基苯氧基基团显著提高了活性。最佳的c-Met激酶抑制活性由2t所体现，IC50 = 2.6 μM，同时在低微摩尔浓度下对TPR-Met磷酸化和BaF3-TPR-Met细胞增殖表现出有效抑制。

  DOI：

  10.1039/c2ob26710a
• 作为产物：
  描述：

  2,3-吡啶二羧酸酐 在 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 氯化亚砜 、 magnesium sulfate 、 N,N-二甲基甲酰胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 48.0h， 生成 5-bromo-N-(4-chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide
  参考文献：
  名称：

  Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties

  摘要：

  Among a large number of HIV-1 integrase (IN) inhibitors, the 8-hydroxy-[1,6]naphthyridines (i.e., L-870,810) were one of the promising class of antiretroviral drugs developed by Merck Laboratories. In spite of its remarkable potency and efficacy, unfortunately upon completion of phase I clinical studies, development of L-870,810 was halted. Because of its desirable pharmacological and pharmaceutical properties we were intrigued to design novel analogues of L-870,810 with goals to (1) improve upon limitations of naphthyridine-7-carboxamides as antiviral agents and (2) to reposition their use as innovative cytotoxic agents for cancer therapeutics. Herein, we report on the design and synthesis of a series of 1,6-naphthyridine-7-carboxamides with various substitutions at the 5- and 8-positions. All the new 5-substituted-8-hydroxy-[1,6]naphthyridines were potent IN inhibitors and the 5-substituted-8-amino-[1,6]naphthyridines were significantly cytotoxic. Further optimization of the 5,8-disubstituted-[1,6]naphthyridines with structural variation on 7-carboxamide delivered novel compounds with significant cytotoxicity in a panel of cancer cell lines and effective inhibition against select oncogenic kinases.

  DOI：

  10.1021/jm300667v

文献信息

• Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> Activity
  作者：Michael G. Thomas、Manu De Rycker、Richard J. Wall、Daniel Spinks、Ola Epemolu、Sujatha Manthri、Suzanne Norval、Maria Osuna-Cabello、Stephen Patterson、Jennifer Riley、Frederick R. C. Simeons、Laste Stojanovski、John Thomas、Stephen Thompson、Claire Naylor、Jose M. Fiandor、Paul G. Wyatt、Maria Marco、Susan Wyllie、Kevin D. Read、Timothy J. Miles、Ian H. Gilbert

  DOI：10.1021/acs.jmedchem.0c00705

  日期：2020.9.10

  tolerated in vivo. Investigation of the mode of action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically active series.

  内脏利什曼病 (VL) 是一种寄生虫感染，每年导致大约 26 000-65 000 人死亡。可用的治疗方法受到毒性、疗效可变和不合适的剂量选择等问题的阻碍。迫切需要新的治疗方法，这导致了被忽视疾病药物计划(DND i )、葛兰素史克 (GSK) 和邓迪大学之间的合作。8-羟基萘啶被确定为起点，早期化合物在 VL 小鼠模型中表现出较弱的功效，但受到葡萄糖醛酸化的阻碍。解决这个问题的努力导致开发了具有改善体外特征的化合物，但这些化合物在体内耐受性差. 对作用方式 (MoA) 的研究表明，活性是由二价金属阳离子的螯合驱动的，这种机制可能导致耐受性差。这突出了在早期研究表型活性系列的 MoA 和药代动力学的重要性。